

A

12/08/97

1511 U.S. PTO

**NEW UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)***(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.

PH1015DB

Total Pages in this Submission

72

TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application****Washington, D.C. 20231**

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

HYDROXY-AMINO ACID AMIDES

and invented by:

Roland Ellwood Dolle, III, Hitesh K. Patel, Theodore O. Johnson, Jr.,
Carolyn DiIanni Carroll, Shiwei Tao

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application No.: 08/743,944

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 51 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☐ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☐ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure
3. ☐ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
 - a. ☐ Formal
 - b. ☐ Informal

Number of Sheets _____

NEW UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
PH1015DB

Total Pages in this Submission
72

Application Elements (Continued)

4. ☒ Oath or Declaration
- a. ☐ Newly executed (*original or copy*) ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
5. ☒ Incorporation By Reference (*usable if Box 4b is checked*)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☐ Genetic Sequence Submission (*if applicable, all must be included*)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (*cover sheet & documents*)
9. ☐ 37 CFR(B) Statement (*when there is an assignee*)
10. ☐ English Translation Document (*if applicable*)
11. ☒ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
☐ First Class ☒ Express Mail (*Specify Label No.*): EM356312311US
15. ☐ Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
16. ☐ Small Entity Statement(s) - Specify Number of Statements Submitted: _____

**NEW UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

PH1015DB

Total Pages in this Submission

72

Accompanying Application Parts (Continued)

17. ☒ Additional Enclosures (please identify below):

Associate Power of Attorney (37 CFR 1.34)

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	12	- 20 =	0	x \$11.00	\$0.00
Indep. Claims	1	- 3 =	0	x \$41.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$395.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$395.00

- ☒ A check in the amount of \$395.00 to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 16-1448 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated:

December 8, 1997

CERTIFICATE OF MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the date shown below and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.


Date: 12/8/97

Janet Rubinstein

(Name of person mailing paper)

Janet B. Rubinstein

(Signature of person mailing paper)


Signature
Vicki H. Audia, Ph.D.
Agent for Applicant
Registration No. 34,539
Pharmacopeia, Inc.
101 College Road East
Princeton, NJ 08540

Express Mail No. EM356312311US
PH1015DB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Dolle et al.
Serial No. : Unknown
Filed : December 8, 1997
For : HYDROXY-AMINO ACID
AMIDES
Group Art Unit :
Examiner :

CERTIFICATE OF MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the date shown below and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Janet B. Rubinstein

(Type or print name of person mailing paper)

Date: 12/8/97

Janet B. Rubinstein

(Signature of person mailing paper)

Princeton, NJ 08540
December 8, 1997

To: Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Entry of this Preliminary Amendment prior to
examination on the merits is respectfully requested.

Please amend the above-identified application as
follows:

IN THE SPECIFICATION:

Page 5, line 6, change "2-amino-3,4-dimethylpentanoic acid" to --isoleucine--.

REMARKS

This Preliminary Amendment is being filed contemporaneously with a divisional application under 37 CFR § 1.53(b) of United States Patent Application 08/743,944 (the "parent application"). As originally filed, the parent application presented claims 1-12. A Restriction Requirement, dated April 11, 1997 in the parent application, divided the claims into three groups, as follows:

I. Claims 1-2 and 4-12 (in part), drawn to compounds of formula I where Y is R⁵ and R⁵ represents a pyrrolidine, classified in class 548.

II. Claims 1-2 and 4-12 (in part), drawn to compounds of formula I where Y is R⁵ and R⁵ represents a piperazine, classified in class 544, as noted in Examiner's action, dated June 12, 1997 in the parent application.

III. Claims 1, 3 and 7-9 (in part), drawn to compounds of formula I where Y is R⁴, classified in various classes and subclasses.


In response to the Restriction Requirement, applicants elected and prosecuted the claims of Group II in the parent application.

Support for the amendment to the specification is found at page 5, line 6; page 7, lines 13-14; and page 4, lines 10-13. The Examiner's Amendment, dated October 10, 1997 in the parent Application supports the change to the specification on page 5, line 6. No new matter has been added.

Applicants respectfully request a favorable action in the present application.

Respectfully submitted,

Dated: December 8, 1997



Vicki H. Audia
Agent For Applicant
Registration No. 34,539
Pharmacopeia, Inc
101 College Road East
Princeton, NJ 08540

HYDROXY-AMINO ACID AMIDES

FIELD OF THE INVENTION

The present invention relates to amino acid (statine) analogs that display selective inhibitory activity against plasmepsin and cathepsin D.

BACKGROUND OF THE INVENTION

Resistance to known antimalarial therapies is becoming an increasing problem and new therapies are therefore desperately needed. Upon infecting a host, the malaria parasite avidly consumes the host hemoglobin as its source of nutrients. Plasmepsin I and II are proteases from *Plasmodium falciparum* that are necessary during the initial stages of hemoglobin hydrolysis and digestion, which primarily occurs in the α -chain, between Phe 33 and Leu 34, although other sites may serve as substrates for hydrolysis as well. It has been shown in cultures inhibition of plasmepsin by a peptidomimetic inhibitor is effective in preventing malarial hemoglobin degradation and in killing the parasite (Francis, S.E., Gluzman, I.Y. Oksman, A., Knickerbocker, A., Mueller, Bryant, M.L., Sherman, D.R., Russell, D.G., and Goldberg, D.E. (1994) *EMBO J*, 13, 306-317). Thus, persons of skill in the art expect that plasmepsin inhibitors will provide effective antimalarial therapy.

Cathepsin D is a human protease in the endosomal-lysosomal pathway, involved in lysosomal biogenesis and protein targeting, and may also be involved in

antigen processing and presentation of peptide fragments. The protease therefore displays broad substrate specificity but prefers hydrophobic residues on either side of the scissile bond.

Cathepsin D has been implicated in a variety of diseases, including connective tissue disease, muscular dystrophy, and breast cancer. Most recently, cathepsin D is believed to be γ -secretase, the protease which processes the β -amyloid precursor protein to generate the C-terminus of β -amyloid (Dreyer, R.N., Bausch, K.M., Fracasso, P., Hammond, L.J., Wunderlich, D., Wirak, D.O., Davis, G., Brini, C.M., Bucholz, T.M., Konig, G., Kamark, M.E., and Tamburini, P.P. (1994) Eur. J. Biochem., 224, 265-271 and Lador, U.S., Synder, S.W., Wang, G.T., Holzman, and Krafft, G.A. (1994) J. Biol. Chem., 269, 18422-18428), which is the major component of plaque in the brains of Alzheimer's patients. Consequently, persons of skill in the art expect that inhibitors of cathepsin D will be useful in treating Alzheimer's disease.


The present invention relates to amino acid (statine) analogs and their inhibitory action against aspartyl proteases, and more particularly, the invention relates to the identification of amino acid analogs that display selective inhibitory activity against plasmepsin and cathepsin D. Although statine-containing peptides are known which inhibit aspartyl proteases (Shewale, J. G.; Takahashi, R.; Tang, J. , *Aspartic Proteinases and Their Inhibitors*, Kostka, V., Ed. Walter de Gruyter: Berlin (1986) pp 101-116), there are only a few selective inhibitors for cathepsin D (Lin, T.-

Y.; Williams, H. R., *Inhibition of Cathepsin D by Synthetic Oligopeptides*, J. Biol. Chem. (1979), 254, 11875-11883; Rich, D. H.; Agarwal, N. S., *Inhibition of Cathepsin D by Substrate Analogues Containing Statine and by Analogues of Pepstatin*, J. Med. Chem. (1986) 29 (2519-2524), and for plasmepsin (Silva, A. M. *et al.*, *Structure and Inhibition of Plasmepsin II, A Hemoglobin-Degrading Enzyme From Plasmodium falciparum*, Proceed Natl Acad Sci, 1996, 93, 10034-10039). The present invention also relates to the solid phase synthesis of such amino acid analogs.

SUMMARY OF THE INVENTION

I. Preferred Embodiments

The compounds of the present invention are represented by Formula I:



wherein:

R¹ and R³ are independently chosen from the group consisting of alkyl, alkoxyalkyl and arylalkyl;

R² is H or $\textcircled{\text{S}}-\text{C}(\text{O})-\text{L}-$

wherein :

$\textcircled{\text{S}}$ is a solid support; and


-L- is a linker; and

Y is -Aa-C(O)R⁴ or -C(O)R⁵;

wherein

Aa is an amino acid attached via its carboxyl to the amine nitrogen of structure I;

R⁴ is chosen from the group consisting of alkyl, aryl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl or substituted heterocycloalkyl; and




wherein

x is 0 or 1;

R⁶ and R⁷ are independently chosen from the group consisting of substituted alkyl, alkylcarbonyl and substituted alkylcarbonyl; and

10 R⁸ is alkyl.

Preferred compounds of Formula I are those wherein -L- is of Formula (a)



wherein the left-hand bond is the point of attachment to -C(O)- and the right hand bond is the point of attachment to the amide nitrogen of structure I.

15 A preferred embodiment of the invention are compounds of Formula I


wherein:

R¹ is chosen from the group consisting of butyl, 3-phenylpropyl and 3-methoxypropyl;

Y is -Aa-C(O)R⁴;

Aa is chosen from the group consisting of valine, leucine, phenylalanine, 2-amino-3,4-dimethylpentanoic acid, β-2-thienylalanine, t-butylglycine, cysteine and phenylglycine; and

R⁴ is chosen from the group consisting of




Another preferred embodiment of the invention are compounds of Formula I

wherein:

- R¹ is chosen from the group consisting of methyl, benzyl, butyl, 3-phenylpropyl, 3-methoxypropyl, 2-pyridinylmethyl and 3-pyridinylmethyl;
- Y is -C(O)R⁵;
- R⁶ is chosen from the group consisting of 3-pyridinylmethyl, phenylethoxyethyl, 3,4,5-trimethoxybenzyl, 4-acetamidobenzyl, 4-phenylbutyl, 3,4-dichlorobenzyl, 4-phenylbenzyl, 3-phenylpropyl, 3,5-bis(trifluoromethyl)benzyl, 3-phenylpropionyl, isobutyl, propionyl and 3,5-di(trifluoromethyl)phenylacetyl; and
- R⁷ is chosen from the group consisting of 4-isopropoxybenzoyl, nicotinoyl, 3,4,5-trimethoxybenzoyl, 3-phenoxybenzoyl, 3-(2-methoxyphenyl)propyl, 3,4,5-trimethoxyphenylpropionyl, 3,3-diphenylpropionyl, phenylacetyl, 3,4-dichlorophenylacetyl and ethyl adipoyl.

A preferred subset of the foregoing embodiment of the invention are compounds of the Formula I wherein:

- R¹ is chosen from the group consisting of methyl, benzyl, butyl, 3-phenylpropyl and 3-methoxypropyl;
- Y is -C(O)R⁵;




R⁶ is chosen from the group consisting of 3-pyridinylmethyl, phenylethoxyethyl, 3,4,5-trimethoxybenzyl, 4-acetamidobenzyl, 4-phenylbutyl, 3,4-dichlorobenzyl, 4-phenylbenzyl, 3,5-bis(trifluoromethyl)benzyl, 3-phenylpropionyl and 3-phenylpropyl; and

R⁷ is chosen from the group consisting of 4-isopropoxybenzoyl, nicotinoyl, 3,4,5-trimethoxybenzoyl, 3-phenoxybenzoyl, 3-(2-methoxyphenyl)propyl, 3,4,5-trimethoxyphenylpropionyl, 3,3-diphenylpropionyl, 3,4-dichlorophenylacetyl and ethyl adipoyl.

A second subset of the second preferred embodiment of the invention are compounds of Formula I wherein

R¹ is chosen from the group consisting of butyl, 2-pyridinylmethyl and 3-pyridinylmethyl;



R⁶ is chosen from the group consisting of 4-phenylbenzyl, isobutyl, propionyl and 3,5-di(trifluoromethyl)phenylacetyl;

R⁷ is chosen from the group consisting of phenylacetyl, 3-phenoxybenzoyl and 3,3-diphenylpropionyl; and

R⁸ is ethyl.

Another aspect of the invention is the use of divinylbenzene-cross-linked, polyethyleneglycol-grafted polystyrene beads optionally functionalized with amino groups (*e.g.*, TentaGel™ S NH₂, Rapp Polymere) as the solid supports for constructing compounds of Formula I.

DETAILED DESCRIPTION OF THE INVENTION

II. Abbreviations and Definitions

The following abbreviations and terms have the indicated meaning throughout:

Alloc	=	allyloxy carbonyl
Bn	=	benzyl
BNB	=	4-bromomethyl-3-nitrobenzoic acid
BOC	=	t-butyloxy carbonyl
Bu	=	butyl
c-	=	cyclo
DCM	=	Dichloromethane = methylene chloride = CH ₂ Cl ₂
DIC	=	diisopropylcarbodiimide
DIEA	=	diisopropylethyl amine
DMAP	=	4-N,N-dimethylaminopyridine
DMF	=	N,N-dimethylformamide
DVB	=	1,4-divinylbenzene

	Et	=	ethyl
	Fmoc	=	9-fluorenylmethoxycarbonyl
	HATU	=	O-(7-Azabenzotriazol-1-yl)1,1,3,3-tetramethyluronium-hexafluorophosphate
5	HOAc	=	acetic acid
	HOBt	=	hydroxybenzotriazole
	m-	=	meta
	Me	=	methyl
	N ₃	=	azido
10	NaBH ₃ CN	=	sodium cyanoborohydride = SCB
	PEG	=	polyethylene glycol
	Ph	=	phenyl
	s-	=	secondary
	t-	=	tertiary
15	TFA	=	trifluoroacetic acid
	THF	=	tetrahydrofuran

“Alkyl” is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. “Lower alkyl” means alkyl groups of from 1 to 8 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s-and t-butyl, pentyl, hexyl, octyl, cyclopropylmethyl, bornyl and the like. Preferred

alkyl groups are those of C₂₀ or below.

“Cycloalkyl” is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 8 carbon atoms. Examples of lower cycloalkyl groups include c-propyl, c-butyl,
5 c-pentyl, norbornyl and the like.

“Alkenyl” includes C₂-C₈ unsaturated hydrocarbons of a linear, branched, or cyclic (C₅-C₆) configuration and combinations thereof. Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, c-hexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl and the like.

10 “Alkynyl” includes C₂-C₈ hydrocarbons of a linear or branched configuration and combinations thereof containing at least one carbon-carbon triple bond. Examples of alkynyl groups include ethyne, propyne, butyne, pentyne, 3-methyl-1-butyne, 3,3-dimethyl-1-butyne and the like.

15 “Alkoxy” refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like.

“Acylamino” refers to acylamino groups of from 1 to 8 carbon atoms of a

straight, branched or cyclic configuration and combinations thereof. Examples include acetylamino, butylamino, cyclohexylamino and the like.

"Halogen" includes F, Cl, Br, and I.

"Aryl" and "heteroaryl" mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, and S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, and S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, and S; each of which rings is optionally substituted with 1-3 lower alkyl, substituted alkyl, substituted alkynyl, = O, -NO₂, halogen, hydroxy, alkoxy, OCH(COOH)₂, cyano, NR¹⁰R¹⁰, acylamino, phenyl, benzyl, phenoxy, benzyloxy, heteroaryl, and heteroaryl or heteroaryloxy; each of said phenyl, benzyl, phenoxy, benzyloxy, heteroaryl, and heteroaryloxy is optionally substituted with 1-3 substituents selected from lower alkyl, alkenyl, alkynyl, halogen, hydroxy, alkoxy, cyano, phenyl, benzyl, benzyloxy, carboxamido, heteroaryl, heteroaryloxy, NO₂, and NR¹⁰R¹⁰;

R¹⁰ is independently H, lower alkyl or cycloalkyl, and -R¹⁰R¹⁰ may be fused to form a cyclic ring with nitrogen.

The aromatic 6- to 14-membered carbocyclic rings include, *e.g.*, benzene,

naphthalene, indane, tetralin, and fluorene and the 5- to 10-membered aromatic heterocyclic rings include, *e.g.*, imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole, and pyrazole.

5 “Arylalkyl” means an alkyl residue attached to an aryl ring. Examples include, *e.g.*, benzyl, phenethyl and the like.

 “Heteroarylalkyl” means an alkyl residue attached to a heteroaryl ring. Examples include, *e.g.*, pyridinylmethyl, pyrimidinylethyl and the like.

10 “Heterocycloalkyl” means a cycloalkyl where one to two of the methylene (CH₂) groups is replaced by a heteroatom such as O, NR’ (wherein R’ is H or alkyl), S or the like; with the proviso that when two heteroatoms are present, they must be separated by at least two carbon atoms. Examples of heterocycloalkyls include tetrahydrofuranyl, piperidine, dioxanyl and the like.

 “Carboxyalkyl” means -C(O)R”, wherein R” is alkyl.

15 “Substituted” alkyl, alkenyl, alkynyl, cycloalkyl, or heterocycloalkyl means alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl wherein up to three H atoms on each C atom therein are replaced with halogen, hydroxy, loweralkoxy, carboxy,

carboalkoxy, carboxamido, cyano, carbonyl, NO_2 , NR^9R^9 (wherein R^9 is H, alkyl or arylalkyl), alkylthio, sulfoxide, sulfone, acylamino, amidino, phenyl, benzyl, heteroaryl, phenoxy, benzyloxy, heteroaryloxy, and substituted phenyl, benzyl, heteroaryl, phenoxy, benzyloxy or heteroaryloxy.

5 Aa represents an amino acid and is intended to include the racemates and all optical isomers thereof. The amino acid side chains of Aa include, *e.g.*, methyl (alanine), hydroxymethyl (serine), phenylmethyl (phenylalanine), thiomethyl (cysteine), carboxyethyl (glutamic acid), *etc.* Primary and secondary amino acids are intended to include alanine, asparagine, N- β -trityl-asparagine, aspartic acid, aspartic acid- β -t-butyl ester, arginine, N⁸-Mtr-arginine, cysteine, S-trityl-cysteine, glutamic acid, glutamic acid- γ -t-butyl ester, glutamine, N- γ -trityl-glutamine, glycine, histidine, N^{im}-trityl-histidine, isoleucine, leucine, lysine, N^e-Boc-lysine, methionine, phenylalanine, proline, serine, O-t-butyl-serine, threonine, tryptophan, Nⁱⁿ-Boc-tryptophan, tyrosine, valine, sarcosine, L-alanine, chloro-L-alanine, 2-aminoisobutyric acid, 2-(methylamino)isobutyric acid, D, L-3-aminoisobutyric acid, (R)-(-)-2 aminoisobutyric acid, (S)-(+)-2-aminoisobutyric acid, 2-thienyalanine, D-norvaline, L-norvaline, L-2-amino-4-pentenoic acid, D-isoleucine, L-isoleucine, D-norleucine, 2,3-diaminopropionic acid, L-norleucine, D,L-2-aminocaprylic acid β -alanine, D,L-3-aminobutyric acid, 4-aminobutyric acid,

15

D,L-4-fluorophenylalanine, D,L-4-chlorophenylalanine, L-4-chlorophenylalanine,
 4-bromo-D,L-phenylalanine, 4-iodo-D-phenylalanine, 3,3',5-triiodo-L-thyronine,
 (+)-3,3',5-triiodo-L-thyronine sodium salt, D-thyronine, L-thyronine, D,L-m-tyrosine,
 D-4-hydroxyphenylglycine, D-tyrosine, L-tyrosine, o-methyl-L-tyrosine, 3-fluoro-
 D,L-tyrosine, 3-iodo-L-tyrosine, 3-nitro-L-tyrosine, 3,5-diiodo-L-tyrosine, D,L-dopa,
 L-dopa, 2,4,5-trihydroxyphenyl-D,L-alanine, 3-amino-L-tyrosine, 4-amino-D-
 phenylalanine,
 4-amino-L-phenylalanine, 4-amino-D,L-phenylalanine, 4-nitro-L-phenylalanine,
 4-nitro-D,L-phenylalanine, 3,5-dinitro-L-tyrosine, D,L- α -methyltyrosine,
 L- α -methyltyrosine, (-)-3-(3,4-dihydroxyphenyl)-2-methyl-L-alanine,
 D,L-threo-3-phenylserine, trans-4-(aminomethyl)cyclohexane carboxylic acid, 4-
 (aminomethyl)benzoic acid, D,L-3-aminobutyric acid, 3-aminocyclohexane
 carboxylic acid, cis-2-amino-1-cyclohexane carboxylic acid, γ -amino- β -(p-
 chlorophenyl) butyric acid (Baclofen), D,L-3-aminophenylpropionic acid, 3-amino-3-
 (4-chlorophenyl) propionic acid, 3-amino-3-(2-nitrophenyl)propionic acid,
 cyclohexylalanine, t-butylglycine, pyridylalanine and 3-amino-4,4,4-trifluorobutyric
 acid.

The statine residues used in this invention were prepared by the method of
 Rich (Rich *et al.*, J. Org. Chem., **43**, 3624 (1978)).

The material upon which the combinatorial syntheses of the invention are

performed are referred to as solid supports, beads or resins. These terms are intended to include beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol and optionally functionalized with amino, hydroxy, carboxy, or halo groups, grafted co-poly beads, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N,N'-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, *etc.*, *i.e.*, material having a rigid or semi-rigid surface; and soluble supports such as low molecular weight non-cross-linked polystyrene.

III. Optical Isomers - Diastereomers - Geometric Isomers

Some of the compounds described herein contain one of more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)-, or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible diastereomers, as well as their racemic and optically pure forms. Optically active (R)- and (S), or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are intended to be included.

IV. Assays for Determining Biological Activity

1. Method for Plasmepsin II

The assay mix contained 50 mM sodium acetate (pH 5.0), 1 mg/ml BSA, 0.01% Tween 20, 12.5% glycerol, 18 % DMSO and 12 μ M plasmepsin substrate. Twenty five μ L of the assay mix was added to each well of a 96-well microtiter plate containing dried down bead eluate or empty control wells. The plates were then sonicated and mixed. 25 μ L of 8 nM plasmepsin II, in 50 mM sodium acetate (pH 5.0), 1 mg/ml BSA, 0.01% Tween 20, and 12.5% glycerol, was added to the assay mix. The final concentrations were 4 nM plasmepsin II, 6 μ M plasmepsin substrate, 9 % DMSO, 50 mM sodium acetate (pH 5.0), 1 mg/ml BSA, 0.01% Tween 20, and 12.5% glycerol. The reaction was incubated for 10 minutes at 25 °C and then quenched by the addition of 25 μ L of 1 M Tris (pH 8.5) and 50 % DMSO to achieve a final concentration of 0.33 M Tris and 23% DMSO. The EDANS fluorescence was measured using a Tecan, SLT FluoStar fluorescence plate reader with an excitation filter of 350 nm and an emission filter 510 nm. The background was determined by 25 μ L of 50 mM sodium acetate (pH 5.0), 1 mg/ml BSA, 0.01% Tween 20, and 12.5% glycerol without enzyme.

2. Method for Cathepsin D

The assay mix contained 25 mM sodium formate (pH 3.5), 1 mg/ml BSA, 12 % DMSO and 12 μ M cathepsin D substrate. Twenty five μ L of the assay mix were added to each well of a 96-well microtiter plate containing dried down bead eluate or

empty control wells. The plates were then sonicated and mixed. 25 μ L of 1.6 nM cathepsin D, in 25 mM sodium formate (pH 3.5), and 1 mg/ml BSA, was added to the assay mix. The final concentrations were 0.8 nM cathepsin D, 6 μ M cathepsin D substrate, 6 % DMSO, 25 mM sodium formate (pH 3.5), and 1 mg/ml BSA. The reaction was incubated for 10 minutes at 25 °C and then quenched by the addition of 25 μ L of 1 M Tris (pH 8.5) and 50% DMSO to achieve a final concentration of 0.33 M Tris and 21 % DMSO. The EDANS fluorescence was measured as stated herein above. The background was determined by 25 μ L of 50 mM sodium formate (pH 3.5), and 1 mg/ml BSA without enzyme.

V. Methods of Synthesis

The compounds of the present invention may be prepared according to the following methods. In carrying out the syntheses, one typically begins with a quantity of solid support that will provide enough compound after cleavage from the solid support for biological testing in the herein described assays. In the case where the solid support is TentaGel™, it is recommended that approximately 0.5 g of beads of about 180 microns in diameter, with a loading capacity of about 300 picoM per bead, be used. As the chemical yield of compounds after photolysis typically ranges from approximately 20% up to 60%, this quantity will provide a yield (approximately >10 mg) sufficient for biological testing in the given protease assays. For actual synthesis, the appropriate reagents and reaction conditions are applied to a reaction vessel containing the specified quantity of beads. During the syntheses, the beads may be

washed free of any excess reagents or by-products before proceeding to the next reaction. At the end of a given reaction sequence, the beads are suspended in a suitable solvent such as methanol and exposed to UV light (365 nm) for 3 hours at room temperature. This protocol releases the compounds of Formula I (wherein R² is H) for purification and biological testing.

A. Scheme 1: Derivatizing resin with bis-Boc lysine

A batch of amino-functionalized PEG-grafted polystyrene beads **3**, *e.g.*, TentaGel™ 3 amine may be modified with bis-Boc lysine **2** to increase the available reaction sites for ligand attachment. Bis-Boc lysine **2** is coupled to the amino-functionalized beads **3** by amide bond formation. Coupling is achieved by reacting a suspension of beads in DCM and adding **2**, HOBt and DIC. The suspension is shaken overnight, drained or filtered, and then washed in succession with DMF, MeOH and DCM, yielding derivatized resin **1** which is then dried overnight under vacuum.

B. Scheme 2

The various amine choices (see Tables 1 and 2) are added to the reaction vessel containing resin **1**. The amines are attached to resin **1** through the photo-labile linker, 4-bromomethyl-3-nitrobenzoic acid. This attachment is accomplished in two steps.

Step 1. The Boc protecting group on resin **1** is removed and the BNB is

attached by the following method. A suspension of resin 1 in 1:1 TFA/DCM is shaken for about 1 hour, then washed with DCM, MeOH, 4:1 MeOH/Et₃N, MeOH, DMF and then DCM. The resultant bis-amine resin 4 is suspended in DCM, and treated with a solution of BNB, HOBt and DIC in DCM. The suspension is shaken for about 3 hours, then drained and washed with DCM. The BNB resin 6 is dried overnight under vacuum.

Step 2. The BNB resin 6 from step 1 are reacted with a unique primary amine (see Tables 1 and 2) to generate compound 7. The coupling of the amine to resin 6 occurs through displacement of the linker bromide and formation of a new carbon-nitrogen bond. As a quality control for the reaction in this step, a small portion of each batch of resin may be removed and titrated with picric acid to determine the extent of amine loading.

C. Scheme 3

Amine 7 is then treated with one of the hydroxy-amino acid reagents (statines) 8 (see Tables 1 and 2). Each hydroxy-amino acid 8 is coupled to amine resin 7 by amide bond formation to produce compound 9.

Compounds 9 may be directed through either the chemistry of Schemes 4 and 5, yielding compounds as in Example 1 and found in Table 1, or in the alternative, through the chemistry of Schemes 6, 7 and 8, yielding compounds as in Example 2

and Table 2.

D. Scheme 4

(With Scheme 5, yields compounds as in Example 1)

Resin **9** is treated with TFA/DCM to remove the Boc protecting group, thus exposing the terminal amino group and forming compounds **10**. Each reaction vessel is then treated with one amino acid **11** (see Table 1), for separate coupling of each amino acid to compound **10** by amide bond formation to produce compounds **12** . The amino acids are introduced with the base-labile Fmoc on the alpha-nitrogen atom.

E. Scheme 5

Compounds **12** are treated with piperidine/DMF to deprotect the amino group by removing the Fmoc protecting group, thus giving rise to compounds **13**, which in turn are treated with one carboxylic acid (see Table 1), which couples with compound **13** to generate compounds **14**. Resin **14** may be cleaved by exposing it to UV light (*ca.* 360 nm) for 15-180 minutes at 25-50 °C in a suitable solvent such as methanol to produce amides of Formula I (wherein R² is H), as in Example 1 and Table 1.

F. Scheme 6

(With Schemes 7 and 8, yields compounds as in Example 2)

Resin **9** (from Scheme 3) is treated with TFA/DCM to remove the Boc protecting group, thus exposing the terminal amino group and forming compounds **10**.

The compound is then treated with one diamino acid **17** (Table 2), for separate coupling of each diamino acid **17** to compounds **10** by amide bond formation, using HATU and DIEA, to produce compounds **18**.

G. Scheme 7

Resin **18** is treated with TFA/DCM to selectively remove the Boc protecting group on the diamino acid ligand to produce amines **19**. The resin is then treated with one carboxylic acid reagent or one carboxyaldehyde (see Table 2) for either separate coupling of each carboxylic acid to compound **19** by amide bond formation or separate reductive amination of each carboxyaldehyde to compound **19** with sodium cyanoborohydride in methanol to produce resin **20**.


H. Scheme 8

Compounds **20** are then treated with palladium tetrakis(triphenylphosphine), tributyltin hydride in acetic acid and DCM to selectively remove the Alloc protecting group on the diamino acid ligand to produce amines **21**. Each vessel is then treated with one carboxylic acid reagent (see Table 2) for separate coupling of the carboxylic acid to compounds **21** by amide bond formation to produce resin **22**. Resin **22** may be cleaved by exposing the resin to UV light (*ca.* 360 nm) for 15-180 minutes at 25-50 °C in a suitable solvent such as methanol to produce amides Formula I (wherein R² is H), as in Example 2 and Table 2.

I. Scheme 9

Diamino acid intermediate **23**, one of the diamine ligands (Table 2), is prepared from hydroxy proline **24** by first treating it with alloxychloroformate, in a solvent such as water, in the presence of a base, *e.g.*, potassium carbonate to yield Alloc protected compound **25**. Compound **25** is esterified with either acid in methanol or diazomethane in diethyl ether, producing ester **26**, which is then converted to bromide compound **27** using a brominating reagent such as triphenylphosphine and carbon tetrabromide. The bromide substituent is in turn displaced with azide using either sodium or potassium azide in DMF. Resultant azide compound **28** is then reductively alkylated with acetaldehyde, by first treating it with triphenylphosphine to generate an imine which is in turn reduced to an N-ethyl amino group in compound **29**. Amine **29** is treated with Boc anhydride in acetonitrile to produce compound **30** which in turn is hydrolyzed to carboxylic acid compound **23** by the action of lithium hydroxide in water.

EXAMPLE 1
ENTRY 11, TABLE 1



Step 1 - Sequential attachment of bis-Boc lysine, photo-labile linker and an amine

1a. Attachment of bis-Boc lysine to TentaGel™

TentaGel™ resin (S-NH₂, 1.0 g, 0.029 mmol/g, 0.29 mmol, 180-220 um) was suspended in a solution of bis-Boc lysine (0.87 mmol, 0.5 g), and HOBt (0.87 mmol, 0.12 g), then treated with DIC (0.17 mmol, 0.27 mL). The suspension was shaken overnight, then drained and washed with 15 mL each DMF (3 x), MeOH (3 x) and DCM (3 x).

1b. Removal of Boc protecting group and attachment of photo-labile linker

A suspension of resin 1 (1.0 g) in 1:1 TFA/DCM was shaken for 1 hour, then washed with 50 mL each DCM (3 x), MeOH (3 x), 4:1 MeOH/Et₃N (1 x), MeOH (3 x), DMF (3 x), then DCM (3 x). This resin was then suspended in 25 mL DCM, then treated with a pre-incubated (45 min) solution of 4-bromomethyl-3-nitro benzoic acid (1.5 mmol, 0.40 g), HOBt (1.5 mmol, 0.23 g), DIC (3.2 mmol, 0.5 mL) in DCM (25 mL). The suspension was shaken for 3 hours, then drained and washed with three 50 mL portions of DCM.

1c. Addition of amine

One gram of the step 1b resin was suspended in THF (50 mL) and then treated with butylamine (5.4 mmol) and shaken overnight. The resin was then drained and washed with 50 mL each DMF (3 x), MeOH (3 x), 10:1 MeOH/TFA (1 x), MeOH (3 x), DMF (3 x), then DCM (3 x).

Step 2 - Addition of phenylalanine-derived statine.

A suspension of the step 1c resin (1.0 g) in DMF (15 mL) was treated with the phenylalanine-derived Boc-protected statine (1.3 mmol), DIEA (2.6 mmol, 0.44 mL), then HATU (1.3 mmol, 0.5 g). This suspension was shaken for 6 hours, drained and washed with 15 mL portions of DMF (3 x), MeOH (3 x), DMF (3 x), and DCM (3 x). The dried resin **9** was divided into two portions.

Step 3 - Deprotection and attachment of Fmoc valine

A suspension of resin **9** (0.5 g) in 40% TFA/ DCM was shaken for 1 hour, then drained and washed with 50 mL each DCM (3 x), MeOH (3 x), 10% Et₃N/MeOH (1 x), MeOH (3 x), and DMF (3 x). The product (0.5 g; 0.33 mmol) was suspended in 10 mL of DMF, containing Fmoc-valine (0.48 mmol) and HATU (0.48 mmol). The suspension was shaken at room temperature for 10 minutes and then DIEA (0.99 mmol) was added. The resulting mixture was shaken for 2 hours, continuously monitoring the resin from the vessel with the Kaiser test to determine the absence of amine functionality. Once the coupling was complete (Kaiser test

negative), the resin was filtered and washed with 10 mL portions of DMF (3 x), MeOH (3 x) and DCM (3 x).

Step 4 - Fmoc-Deprotection.

The resin (0.5 g) was suspended in 30% piperidine in DMF (15 mL) and shaken for 1 hour at room temperature. The resin was filtered, washed with 15 mL portions of DMF (2 x), DCM (3 x), MeOH (3 x) and DCM (5 x), then dried under vacuum.

Step 5 - Attachment of 2,4-dimethoxybenzoic acid


The resin in a reaction vessel was combined with 2,4-dimethoxybenzoic acid (0.6 mmol), HATU (0.72 mmol) and DIEA (1.8 mmol) in DMF (15 mL). The resulting suspension of resin was shaken for approximately one hour at room temperature, at which time the Kaiser test was negative. The resin was filtered and washed with 10 mL each DMF (2 x), MeOH (3 x) and DCM (5 x). The resin was filtered and subjected to a wash cycle consisting of 10 mL portions each TFA/water (1:1) (2 x), DMF (2 x), MeOH (4 x), DMF (2 x) and DCM (5 x), then dried in vacuum.

Step 6 - Cleavage by light

The resin was suspended in MeOH (20 mL) and the compound cleaved from the resin at 50 °C, then light (365 nm) was shone on them for 3 to 4 hours. The

suspension was filtered, the MeOH removed to give the title compound as confirmed by mass spectroscopy (mass spectrum (fab): $m/z = 528$ (MH^+)).

EXAMPLE 2
ENTRY 16, TABLE 2



Step 1- Deprotection and attachment of diamino acid

A suspension of resin **9** (0.5 g) in 40% TFA/DCM, prepared as in Example 1, with the exception that 3-methoxypropylamine was used in place of butylamine, was shaken for 1 hour, then drained and washed with 50 mL portions of DCM (3 x), MeOH (3 x), 10% Et₃N/MeOH (1 x), MeOH (3 x) and DMF (3 x). A suspension of this resin in DMF (50 mL) was treated with the corresponding diamino carboxylic acid (entry 16, Table 2; 1.6 mmol), DIEA (3.3 mmol), then HATU (1.7 mmol). The suspension was shaken for 6 hours, then drained and washed with 50 mL portions of DMF (3 x), MeOH (3 x), DMF (3 x), then DCM (3 x) and filtered. The resin was

dried in *vacuo*.

Step 2 - Deprotection and attachment of a carboxyaldehyde

5 A suspension of resin batch one (0.5 g) in 40% TFA/DCM (10 mL) was shaken for 1 hour, then drained and washed with 10 mL portions of DCM (3 x), MeOH (3 x), 10% Et₃N/MeOH (1 x), MeOH (3 x), and DMF (3 x). This resin, suspended in 2% HOAc/DMF (10 mL), was treated with 3-phenylpropionyl (8.8 mmol), followed by the addition of NaBH₃CN (4.4 mmol, 0.28 g). The resin was shaken overnight, then drained and washed with 10 mL portions of DMF (3 x), MeOH (3 x), then DMF (3 x), DCM (3 x). The resin was dried in *vacuo*.

Step 3 - Deprotection and attachment of 3-(2,3,4-trimethoxyphenyl)propionoic acid

15 A suspension of resin (0.5 g) in DCM (10 mL) was treated with HOAc (4.8 mmol, 0.27 mL), Pd(PPh₃)₄ (0.072 mmol, 83 mg), then Bu₃SnH (2.4 mmol, 0.64 mL). This suspension was shaken for 1 hour, then drained and washed with 10 mL portions of DCM (3 x), pyridine (3 x), DCM (3 x), then DMF (3 x). The resin in DMF (10 mL) was then treated with 3-(2,3,4-trimethoxyphenyl)propionoic acid (0.36 mmol), followed by DIEA (0.72 mmol, 0.13 mL), and HATU (0.36 mmol, 0.14 g). This suspension was shaken for 6 hours, then drained and washed with 10 mL portions of DMF (3 x), MeOH (3 x), then DMF (3 x) and DCM (3 x).


Step 4 - Cleavage by light

The resin was suspended in MeOH (20 mL) and the compound cleaved from the resin at 50 °C, then light (365 nm) was shone on them for 3 to 4 hours. The suspension was filtered, the MeOH removed to give the title compound as confirmed by mass spectroscopy (mass spectrum (fab): $m/z = 719$ (MH^+)).

Using these methods, compounds in Tables 1 and 2 were prepared. The compounds in Tables 1 and 2 typically show greater than 2-fold selectivity for either plasmepsin or cathepsin D at an inhibitory activity (IC_{50}) less than 10 micromolar.


03986545-120897

Table 1. R Groups for Compounds of Formula I where Y is an amino acid




Entry	R ¹	R ³	R ⁹	R ⁴
1	butyl	CH ₂ Ph	CH(Me)CH ₂ Me	
2	butyl	CH ₂ Ph	CH(Me)CH ₂ Me	
3	3-phenylpropyl	CH ₂ Ph	CH(Me)CH ₂ Me	
4	butyl	CH ₂ CH(Me) ₂	CH(Me) ₂	octyl
5	3-phenylpropyl	CH ₂ CH(Me) ₂	CH(Me)CH ₂ Me	
6	3-phenylpropyl	CH ₂ CH(Me) ₂	CH(Me)CH ₂ Me	
7	butyl	CH ₂ Ph	CH(Me) ₂	
8	3-phenylpropyl	CH ₂ Ph	CH(Me) ₂	
9	3-phenylpropyl	CH ₂ Ph	CH(Me)CH ₂ Me	
10	3-phenylpropyl	CH ₂ Ph	CH(Me)CH ₂ Me	
11	butyl	CH ₂ Ph	CH(Me) ₂	

Table 1 (continued). R Groups for Compounds of Formula I where Y is an amino acid




Entry	R ¹	R ³	R ⁹	R ⁴
12	butyl	CH ₂ CH(Me) ₂	Ph	
13	3-methoxypropyl	CH ₂ CH(Me) ₂	CH ₂ SH	
14	butyl	CH ₂ CH(Me) ₂	CH ₂ CH(Me) ₂	
15	butyl	CH ₂ CH(Me) ₂	CH ₂ Ph	
16	butyl	CH ₂ CH(Me) ₂	CH ₂ (2-thienyl)	
17	butyl	CH ₂ Ph	Ph	
18	butyl	CH ₂ CH(Me) ₂	C(Me) ₃	(CH ₂) ₃ -O-(2,4-di-Cl)Ph
19	3-methoxypropyl	CH ₂ Ph	Ph	(CH ₂) ₃ -O-(2,4-di-Cl)Ph
20	butyl	CH ₂ Ph	Ph	
21	butyl	CH ₂ Ph	Ph	(2,4-di-OMe)phenyl

Table 2. R Groups for Compounds of Formula I where Y is the diamino acid




Entry	R^1	R^3	n	R^6	R^7
1	benzyl	Me	0	3-pyridinylmethyl	4-isopropoxybenzoyl
2	butyl	CH_2Ph	0	$Ph(CH_2)_2O(CH_2)_2-$	(3,4,5-tri-OMe)benzoyl
3	butyl	CH_2Ph	0	4-phenylbenzyl	(3,4,5-tri-OMe)benzoyl
4	butyl	CH_2Ph	1	(3,4,5-tri-OMe)benzyl	4-isopropoxybenzoyl
5	butyl	CH_2Ph	1	(4-MeC(O)NH)PhCH ₂ -	3-phenoxybenzoyl
6	3-phenylpropyl	CH_2Ph	0	4-phenylbutyl	(3,4,5-tri-OMe)benzoyl
7	butyl	CH_2Ph	0	(4-MeC(O)NH)PhCH ₂ -	(3,4,5-tri-OMe)benzoyl
8	butyl	CH_2Ph	0	3,4-di-Cl-benzyl	(3,4,5-tri-OMe)benzoyl
9	butyl	CH_2Ph	0	4-phenylbenzyl	(3,4,5-tri-OMe)benzoyl
10	butyl	CH_2Ph	1	(3,4,5-tri-OMe)benzyl	3-phenoxybenzoyl
11	methyl	CH_2Ph	0	4-phenylbenzyl	3-phenoxybenzoyl
12	3-methoxypropyl	CH_2Ph	1	3,5-bis-trifluoromethylbenzyl	4-isopropoxybenzoyl
13	butyl	CH_2Ph	0	3-phenylpropyl	(3,4,5-tri-OMe)benzoyl
14	methyl	CH_2Ph	0	4-phenylbenzyl	3-(2-OMe-phenyl)propyl
15	methyl	CH_2Ph	0	3,4-di-Cl-benzyl	nicotinoyl

Table 2 (continued). R Groups for Compounds of Formula I where Y is a diamino acid




Entry	R ¹	R ³	n	R ⁶	R ⁷
16	3-phenylpropyl	CH ₂ Ph	0	3-phenylpropyl	(3,4,5-tri-OMe-phenyl)propionyl
17	butyl	CH ₂ CH(Me) ₂	0	3-phenylpropionyl	3,3-diphenylpropionyl
18	3-methoxypropyl	CH ₂ Ph	0	4-phenylbenzyl	3,3-diphenylpropionyl
19	butyl	CH ₂ Ph	1	4-phenylbenzyl	3,4-di-Cl-phenylacetyl
20	butyl	CH ₂ Ph	0	(3,4,5-tri-OMe)benzyl	(3,4,5-tri-OMe-phenyl)propionyl
21	methyl	CH ₂ Ph	0	3,4-di-Cl-benzyl	EtOC(O)(CH ₂) ₄ C(O)-
22	butyl	CH ₂ Ph	0	EtOC(O)(CH ₂) ₄ C(O)-	3,4,5-tri-OMe)benzoyl




Entry	R ¹	R ³	R ⁶	R ⁷
23	butyl	CH ₂ Ph	4-phenylbenzyl	phenylacetyl
24	2-pyridinylmethyl	CH ₂ Ph	Me ₂ CHCH ₂ -	3-phenoxybenzoyl
25	3-pyridinylmethyl	CH ₂ CH(Me) ₂	propionyl	3,3-diphenylpropionyl
26	3-pyridinylmethyl	CH ₂ Ph	3,5-di-CF ₃ -phenylacetyl	3,3-diphenylpropionyl

Scheme 1
Attachment of Bis-Boc lysine to resin




Scheme 2
Attachment of BNB linker and addition of amine


Step (1): BNB attachment:



Step (2): Amine attachment:




Scheme 3
Attachment of hydroxy-amino acids



(for the selection of
hydroxy-amino acids
-see Tables 1&2)




0898545 120897

Scheme 4
Removal of BOC-protecting group and attachment of FMOC-amino acids




Scheme 5

Removal of Fmoc-protecting group, attachment of N-terminal R⁴ groups and cleavage




(See Example 1
and compounds in Table 1)

Scheme 6
Removal of BOC-protecting group and attachment of diamino acids




Scheme 7
Removal of the BOC-protecting group and acylation or
reductive amination of secondary amine



2021-05-14 14:54:54


Scheme 8
Removal of the Alloc-protecting group and acylation of
secondary amine



(Library of Example and
compounds of Table 2)

268021 5458680


Scheme 9
Preparation of Carboxylic Acid 23



CLAIMS

We claim:

1. A compound of Formula I



wherein:

R¹ and R³ are independently chosen from the group consisting of alkyl, alkoxyalkyl

and arylalkyl;

R² is H or $\textcircled{\text{S}}-\text{C}(\text{O})-\text{L}-$;

wherein :

$\textcircled{\text{S}}$ is a solid support; and

-L- is a linker; and

Y is -Aa-C(O)R⁴ or -C(O)R⁵


wherein

Aa is an amino acid attached via its carboxyl to the amine nitrogen of structure I;

R⁴ is chosen from the group consisting of alkyl, aryl, substituted alkyl,

cycloalkyl, substituted cycloalkyl, heterocycloalkyl and substituted

heterocycloalkyl; and



wherein

18 x is 0 or 1;

19 R^6 and R^7 are independently chosen from the group consisting of substituted alkyl,

20 alkylcarbonyl and substituted alkylcarbonyl; and

21 R^8 is alkyl.

2. A compound according to claim 1 wherein R^2 is hydrogen .

3. A compound according to claim 2 wherein

R^1 is chosen from the group consisting of butyl, 3-phenylpropyl and

3-methoxypropyl;


Y is $-Aa-C(O)R^4$;

Aa is chosen from the group consisting of valine, leucine, phenylalanine,

2-amino-3,4-dimethylpentanoic acid, β -2-thienylalanine, t-butylglycine,

cysteine and phenylglycine; and

R^4 is chosen from the group consisting of



4. A compound according to claim 2 wherein

R^1 is chosen from the group consisting of methyl, benzyl, butyl, 3-phenylpropyl, 3-methoxypropyl, 2-pyridinylmethyl and 3-pyridinylmethyl;

Y is $-C(O)R^5$;


R^6 is chosen from the group consisting of 3-pyridinylmethyl, phenylethoxyethyl, 3,4,5-trimethoxybenzyl, 4-acetamidobenzyl, 4-phenylbutyl, 3,4-dichlorobenzyl, 4-phenylbenzyl, 3-phenylpropyl, ethyl adipoyl, 3,5-bis(trifluoromethyl)benzyl, 3-phenylpropionyl, isobutyl, propionyl and 3,5-di(trifluoromethyl)phenylacetyl; and

R^7 is chosen from the group consisting of 4-isopropoxybenzoyl, nicotinoyl, 3,4,5-trimethoxybenzoyl, 3-phenoxybenzoyl, 3-(2-methoxyphenyl)propyl, 3,4,5-trimethoxyphenylpropionyl, 3,3-diphenylpropionyl, phenylacetyl, 3,4-dichlorophenylacetyl and ethyl adipoyl.

5. A compound according to claim 4 wherein

R^1 is chosen from the group consisting of methyl, benzyl, butyl, 3-phenylpropyl and 3-methoxypropyl;

R^5 is




wherein

R^6 is chosen from the group consisting of 3-pyridinylmethyl, phenylethoxyethyl, 3,4,5-trimethoxybenzyl, 4-acetamidobenzyl, 4-phenylbutyl, ethyl adipoyl, 3,4-dichlorobenzyl, 4-phenylbenzyl, 3,5-bis(trifluoromethyl)benzyl, 3-phenylpropionyl and 3-phenylpropyl; and

R^7 is chosen from the group consisting of 4-isopropoxybenzoyl, nicotinoyl, 3,4,5-trimethoxybenzoyl, 3-phenoxybenzoyl, 3-(2-methoxyphenyl)propyl, 3,4,5-trimethoxyphenylpropionyl, 3,3-diphenylpropionyl, 3,4-dichlorophenylacetyl; and ethyl adipoyl.

6. A compound according to claim 4 wherein

R^1 is chosen from the group consisting of butyl, 2-pyridinylmethyl and 3-pyridinylmethyl;




wherein

- R^6 is chosen from the group consisting of 4-phenylbenzyl, isobutyl, propionyl and 3,5-di(trifluoromethyl)phenylacetyl;
- R^7 is chosen from the group consisting of phenylacetyl, 3-phenoxybenzoyl and 3,3-diphenylpropionyl; and
- R^8 is ethyl.

7. A compound according to claim 1 wherein R^2 is $\textcircled{S}-C(O)-L-$.

8. A compound according to claim 7 wherein $-L-$ is



wherein the left-hand bond is the point of attachment to $-C(O)-$ and the right-hand bond is the point of attachment to the amide nitrogen of structure I.

9. A compound according to claim 7 wherein


R^1 is chosen from the group consisting of butyl, 3-phenylpropyl and 3-methoxypropyl;

Y is $-Aa-C(O)R^4$;

Aa is chosen from the group consisting of valine, leucine, phenylalanine, 2-amino-3,4-dimethylpentanoic acid, β -2-thienylalanine, t-butylglycine,

cysteine and phenylglycine; and

R^4 is chosen from the group consisting of



10. A compound according to claim 7 wherein

R^1 is chosen from the group consisting of methyl, benzyl, butyl, 3-phenylpropyl, 3-methoxypropyl, 2-pyridinylmethyl and 3-pyridinylmethyl;

Y is $-C(O)R^5$;

R^6 is chosen from the group consisting of 3-pyridinylmethyl, phenylethoxyethyl, 3,4,5-trimethoxybenzyl, 4-acetamidobenzyl, 4-phenylbutyl, 3,4-dichlorobenzyl, 4-phenylbenzyl, 3-phenylpropyl, ethyl adipoyl, 3,5-bis(trifluoromethyl)benzyl, 3-phenylpropionyl, isobutyl, propionyl and 3,5-di(trifluoromethyl)phenylacetyl; and


R^7 is chosen from the group consisting of 4-isopropoxybenzoyl, nicotinoyl, 3,4,5-trimethoxybenzoyl, 3-phenoxybenzoyl, 3-(2-methoxyphenyl)propyl,

3,4,5-trimethoxyphenylpropionyl, 3,3-diphenylpropionyl, phenylacetyl,
3,4-dichlorophenylacetyl and ethyl adipoyl.

11. A compound according to claim 10 wherein

R^1 is chosen from the group consisting of methyl, benzyl, butyl, 3-phenylpropyl
and 3-methoxypropyl;

R^5 is




wherein

R^6 is chosen from the group consisting of 3-pyridinylmethyl, phenylethoxyethyl,
3,4,5-trimethoxybenzyl, 4-acetamidobenzyl, 4-phenylbutyl, ethyl adipoyl,
3,4-dichlorobenzyl, 4-phenylbenzyl, 3,5-bis(trifluoromethyl)benzyl,
3-phenylpropionyl and 3-phenylpropyl; and

R^7 is chosen from the group consisting of 4-isopropoxybenzoyl, nicotinoyl, 3,4,5-
trimethoxybenzoyl, 3-phenoxybenzoyl, 3-(2-methoxyphenyl)propyl, 3,4,5-
trimethoxyphenylpropionyl, 3,3-diphenylpropionyl, 3,4-dichlorophenylacetyl
and ethyl adipoyl.

12. A compound according to claim 10 wherein

R^1 is chosen from the group consisting of butyl, 2-pyridinylmethyl and 3-pyridinylmethyl;




R^6 is chosen from the group consisting of 4-phenylbenzyl, isobutyl, propionyl and 3,5-di(trifluoromethyl)phenylacetyl;

R^7 is chosen from the group consisting of 3-phenoxybenzoyl, 3,3-diphenylpropionyl and phenylacetyl; and

R^8 is ethyl.

HYDROXY-AMINO ACID AMIDES**ABSTRACT OF THE INVENTION**

Compounds of Formula I



are disclosed as inhibitors of plasmepsin and cathepsin D. The compounds are therefore useful to treat diseases such as malaria. In preferred compounds of formula I, Y is the residue of an N-acylated amino acid, a substituted 4-aminoproline or a substituted piperazinealkanoic acid. Intermediates in the solid phase synthesis of compounds of formula I, in which the compounds are attached to a solid support, are also disclosed.

Docket No.

1073.010

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HYDROXY-AMINO ACID AMIDES

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on November 5, 1996 as United States Application No. or PCT International Application Number 08/743,944 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112. I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Candice J. Clement	Reg. No. 39,946
Philip E. Hansen	Reg. No. 32,700
Martha L. Boden	Reg. No. 39,115
Robert E. Heslin	Reg. No. 24,778
Jeff Rothenberg	Reg. No. 26,429

All of Heslin & Rothenberg, P.C.
5 Columbia Circle
Albany, New York 12203

Send Correspondence to: Candice J. Clement
Heslin & Rothenberg, P.C.
5 Columbia Circle
Albany, New York 12203

Direct Telephone Calls to: *(name and telephone number)*
Candice J. Clement, (518) 452-5600

Full name of sole or first inventor Roland Ellwood Dolle III	
Sole or first inventor's <i>Roland Ellwood Dolle III</i>	Date <i>1/2/97</i>
Residence 550 Prince Frederick Street, King of Prussia, Pennsylvania 19406	
Citizenship United States of America	
Post Office Address 550 Prince Frederick Street, King of Prussia, Pennsylvania 19406	

Full name of second inventor, if any Hitesh K. Patel	
Second inventor's signature <i>Hitesh K. Patel</i>	Date <i>1/2/97</i>
Residence Petunia Drive, Bldg. 9, Apt. 2D, North Brunswick, New Jersey 08902	
Citizenship United Kingdom	
Post Office Address Petunia Drive, Bldg. 9, Apt. 2D, North Brunswick, New Jersey 08902	

Full name of third inventor, if any Theodore O. Johnson, Jr.	
Third inventor's signature <i>Theodore O. Johnson Jr.</i>	Date 1-2-97
Residence 8 Henry Court, Plainsboro, New Jersey 08536	
Citizenship United States of America	
Post Office Address 8 Henry Court, Plainsboro, New Jersey 08536	

Full name of fourth inventor, if any Carolyn DiIanni Carroll	
Fourth inventor's signature <i>Carolyn DiIanni Carroll</i>	Date 1/2/97
Residence 479 Robins Court, Yardley, Pennsylvania 19067	
Citizenship United States of America	
Post Office Address 479 Robins Court, Yardley, Pennsylvania 19067	

Full name of fifth inventor, if any Shiwei Tao	
Fifth inventor's signature <i>Shiwei Tao</i>	Date 1/2/97
Residence 19-02 Fox Run Drive, Plainsboro, New Jersey 08536	
Citizenship Peoples Republic of China	
Post Office Address 19-02 Fox Run Drive, Plainsboro, New Jersey 08536	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Dolle et al.
Serial No. : Not yet known
Filed : December 8, 1997
For : Hydroxy-Amino Acid Amides
Group Art Unit :
Examiner :

CERTIFICATE OF MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the date shown below and is addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Janet B. Rubinstein

(Type or print name of person mailing paper)

Date: 12/8/97

Janet B. Rubinstein

(Signature of person mailing paper)

Assistant Commissioner for Patents
Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY (37 CFR 1.34)

Dear Sir:

Please recognize Vicki H. Audia, Ph.D. (Registration No. 34,539) as an associate attorney in the application filed herewith.

Please address all future communications to:

VICKI H. AUDIA, PH.D.
PATENT AGENT
PHARMACOEPIA, INC.
101 COLLEGE ROAD EAST
PRINCETON, NJ 08540

TEL. NO.: (609) 452-3609
FAX NO.: (609) 452-2434

Respectfully submitted,

Date: December 4, 1997

Candice J. Clement

Candice J. Clement
Registration No.: 39,946
Attorney for Applicant
Heslin & Rothenberg, P.C.
5 Columbia Circle
Albany, NY 12203
Telephone: (518) 452-5600